2-methyl-N-[5-(4-piperidinyl)-3-pyridinyl]propanamide → HCID 18446879、化合物
反応式
Br[CH2:2][CH2:3][CH2:4][NH:5][C:6](=[O:20])[CH:7]([C:14]1[CH:19]=[CH:18][CH:17]=[CH:16][CH:15]=1)[C:8]1[CH:13]=[CH:12][CH:11]=[CH:10][CH:9]=1.[CH3:21][CH:22]([CH3:38])[C:23]([NH:25][C:26]1[CH:27]=[N:28][CH:29]=[C:30]([CH:32]2[CH2:37][CH2:36][NH:35][CH2:34][CH2:33]2)[CH:31]=1)=[O:24]>>[C:8]1([CH:7]([C:14]2[CH:19]=[CH:18][CH:17]=[CH:16][CH:15]=2)[C:6]([NH:5][CH2:4][CH2:3][CH2:2][N:35]2[CH2:36][CH2:37][CH:32]([C:30]3[CH:31]=[C:26]([NH:25][C:23](=[O:24])[CH:22]([CH3:21])[CH3:38])[CH:27]=[N:28][CH:29]=3)[CH2:33][CH2:34]2)=[O:20])[CH:13]=[CH:12][CH:11]=[CH:10][CH:9]=1参加物
3
実験手順
Example 170 was prepared from N-(3-bromopropyl)-2,2-diphenylacetamide and 2-methyl-N-[5-(4-piperidinyl)-3-pyridinyl]propanamide according to the procedures described in Scheme 14: 1H NMR (400 MHz, CDCl3) δ 8.47–8.42 (m, 1 H), 8.21–8.16 (m, 1 H), 8.09 (s, 1 H), 7.59 (s, 1 H), 7.35–7.20 (m, 10 H), 6.87 (s, 1 H), 4.91 (s, 1 H), 3.46–3.36 (m, 2 H), 3.01–2.92 (m, 2 H), 2.62–2.47 (m, 2 H), 2.47–2.37 (m, 2 H), 2.11–1.94 (m, 4 H), 1.86–1.59 (m, 4 H), 1.25 (d, 6 H, J=7.2 Hz); ESMS m/e: 499.4 (M+H)+.
出典と根拠
- ORDレコード
- ord-d9301ffd6ad0417a900a043bcbe57d46
- 出典データセット
- uspto-grants-2007_04